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I rritable bowel syndrome (IBS) is a disorder of gut–brain interaction (previously referred to as a functional gastro­intestinal disorder), characterized by abdominal pain associ­
ated with a change in frequency or form of bowel habit. Irritable 
bowel syndrome accounts for more than 40% of new referrals to 
gastroenterology outpatient clinics, although the disease is 
mostly managed by primary care practitioners.1–3 We summarize 
the epidemiology, pathophysiology, differential diagnosis and 
management of IBS, drawing on best available evidence (Box 1) 
to guide family physicians and nonspecialists in management of 
this condition.
What is the burden of IBS?
Irritable bowel syndrome is common, affecting 3.7% of men and 
7.8% of women in Canada, with a peak incidence in ages 
18–34 years.4 The incidence of IBS has been reported to be about 
4 new cases per 1000 patients per year.5 In 2005, the annual 
direct medical costs of IBS per annum worldwide were estimated 
to be US$1.5–$10 billion, excluding over­the­counter and pre­
scription medication costs.1 Irritable bowel syndrome is also 
associated with increased work absenteeism and poor work pro­
ductivity because of symptoms, with associated annual costs to 
employers of Can$2200 per patient.6
Which clinical features typify IBS?
The diagnosis of IBS is symptom­based. The diagnostic criteria 
are recurrent abdominal pain (occurring on average at least 
1 day per week in the previous 3 months, with the onset of 
symptoms occuring at least 6 months before diagnosis) with at 
least 2 of the following: related to defecation, associated with a 
change in stool frequency, and associated with a change in stool 
appearance.1 Patients with IBS usually present with symptoms 
of recurrent abdominal pain and a change in stool form or fre­
quency.1 Stool changes can manifest as diarrhea or constipation 
or an alternation between the two. Abdominal pain is frequently 
associated with defecation. Extragastrointestinal symptoms are 
also common and include headache, dysmenorrhea, dyspareu­
nia and fatigue. Irritable bowel syndrome frequently occurs in 
patients with other medically unexplained or affective disor­
ders, such as fibromyalgia, depression or anxiety.7 Furthermore, 
patients with IBS may have other overlapping disorders of gut–
brain interaction, such as functional dyspepsia.8 Symptoms typ­
ically vary in frequency and intensity, and are often aggravated 
by stress.9
The Rome Foundation (https://theromefoundation.org/
about) has sought to systematize, evaluate and revise the defini­
tion of IBS using a multi national expert process. The current 
Rome IV classification is the culmination of the evolution of a 
series of iterations (Rome I–Rome III).1 The Rome criteria cur­
rently divide IBS into 4 subtypes based on the most prominent 
bowel habit: IBS with constipation (IBS­C), IBS with diarrhea 
(IBS­D), IBS with mixed bowel habit (IBS­M; with alternating 
between constipation and diarrhea) and IBS unclassified (IBS­U) 
(Figure 1).1 The most frequent subtype is IBS­D, accounting for 
about 40% of patients.10 Although IBS in general is more com­
mon among women, IBS­D is more common among men.10 
There are considerable geographic and ethnic differences in 
health care seeking that affect epidemiological estimates.10 A 
population­based study showed that health care seeking was 
independently associated with severity and duration of the pain 
rather than psychological factors.11
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KEY POINTS
• Irritable bowel syndrome (IBS) is a common disorder 
characterized by chronic abdominal pain that is associated with 
a change in frequency or form of bowel habit.
• The underlying pathophysiology of IBS is incompletely 
understood.
• The differential diagnosis of IBS is broad and, in conjunction 
with targeted investigations, the diagnosis is symptom­based.
• The syndrome can be usefully subdivided according to its 
predominant bowel habit.
• Treatments are multifaceted; they include education and 
reassurance, dietary modifications and pharmaceutical 
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What causes IBS?
The condition is currently considered to be a manifestation of 
bidirectional disordered communication within the brain–gut axis 
that influences gastrointestinal motility, secretion and sensation.12 
Within this construct, a number of elements such as genetic 
factors,13 personality traits,14 alterations in the stress­responsive 
physiologic systems,15 low­grade gastrointestinal inflammation,16 
changes within the microbiota17 and the sequelae of enteric 
infections (termed postinfectious IBS),18 have all been proposed as 
being important in the development and maintenance of the 
disorder19 (Figure 2). However, the pathophysiology of IBS is not 
fully understood.
Which differential diagnoses should be 
considered before making a diagnosis of IBS?
Given the relative lack of symptom specificity, the differential 
diagnosis of IBS is broad and includes inflammatory bowel dis­
ease (IBD), celiac disease, bile acid diarrhea and carbohydrate 
malabsorption (e.g., lactose intolerance).21 It is important to 
exclude serious conditions by looking specifically for “alarm 
symptoms” or “red flags” that may indicate neoplasm, includ­
ing those listed in Box 2. However, using the diagnostic criteria 
mentioned above, and in the absence of red flag symptoms, 
IBS can be diagnosed without the need for extensive investiga­
tions.22 In patients with IBS­D, complete blood count, inflam­
matory markers (e.g., C­reactive protein), ferritin, vitamin B12, 
folate and celiac serologic (immunoglobulin A tissue transglu­
taminase) testing are helpful to exclude iron deficiency anemia, 
malabsorption and celiac disease. A 2015 meta­analysis of 
studies of diagnostic tests found that a normal fecal calprotec­
tin level has a high negative predictive value for IBD,23 although 
absolute cut­off values vary from assay to assay and from lab­
oratory to laboratory.
The symptoms of bile acid diarrhea are indistinguishable from 
IBS­D, and about 30% of patients who meet the Rome criteria for 
IBS­D have bile acid diarrhea.24 Depending on local availability of 
tests, bile acid diarrhea can be diagnosed using investigations 
such as 23­seleno­25­homo­taurocholic acid (SeHCAT) nuclear 
medicine testing, serum 7­α­hydroxy­4­cholesten­3­one (C4) or 
measurement of fecal bile acids. It is important to consider this 
differential in patients who have undergone cholecystectomy, as 
bile acid diarrhea frequently responds to bile acid sequestrants, 
such as cholestyramine or colesevelam. For IBS­C, a detailed his­
tory needs to be taken to exclude secondary causes of constipa­
tion (e.g., diuretics, opioids and drugs with an anticholinergic 
mechanism of action).
How is IBS managed?
The clinical management of IBS can be challenging. Developing a 
positive therapeutic relationship with patients, underpinned by 
patient education, is key to optimizing clinical outcomes.25 Man­
aging the bothersome symptoms is the mainstay of IBS treat­
ment. When the condition is difficult to manage, care by a multi­
disciplinary team that includes specialist nurses, dietitians, 
liaison psychiatrists and psychologists can improve outcomes, 
although access to such services markedly depends on local ser­
vice provision.26 Comprehensive guidelines regarding the man­
agement of IBS are available from the Canadian Digestive Health 
Foundation and the American College of Gastroenterology.6,26 A 
summary management algorithm is shown in Figure 3.
Broadly, clinicians should conduct a careful and detailed 
evalu ation of symptom onset and the effect on the patient’s qual­
ity of life, and explain that the diagnosis is symptom­based, that 
multiple investigations are not usually needed and that targeted 
treatment can improve quality of life. It is important to explain 
that IBS is a relapsing and remitting disorder in which the pre­
dominant bowel habit and symptoms can change over time, that 
it is not a progressive inflammatory disorder like inflammatory 
bowel disease (with which patients may confuse it), and that can­
cer is unlikely in the absence of red flag symptoms. Physicians 
may direct patients to reliable online sources of information and 
peer­group support, such as the Canadian Society of Intestinal 
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Figure 1: Classification of the different subtypes of inflammatory bowel 
disease (IBS) according to the predominant bowel habit: IBS with constipa­
tion (IBS­C), IBS with diarrhea (IBS­D), IBS with mixed bowel habit (IBS­M) 
and IBS unclassified (IBS­U).
Box 1: Literature search
We searched PubMed (1946–September 2019), Embase and Embase 
Classic (1947–September 2019), and the Cochrane Central Register 
of Controlled Trials using the terms “irritable bowel syndrome” and 
“IBS,” both on their own and with the AND function, including the 
terms “pathophysiology,” “treatment” and “drugs.” We drew on 
relevant research conducted in human adult populations, focusing 
mainly on guidelines, meta­analyses and clinical trials.
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Lifestyle and dietary interventions
The guideline from the American College of Gastroenterology 
states that increasing exercise can lead to overall symptom 
improvement in IBS, although the evidence for this recommen­
dation is weak.26 Studies suggest that 70%–84% of patients with 
IBS report that certain food groups exacerbate their symptoms 
and dietary modifications can be useful.28,29
A number of randomized controlled trials (RCTs) have examined 
the effects on IBS of reducing dietary intake of fermentable oligo­, di­, 
monosaccharides and polyols (FODMAP) — fermentable carbohy­
drates that are thought to cause an osmotic effect and increase intra­
colonic fermentation to cause gaseous distension.30,31 Food groups 
that are high in FODMAPs include legumes, fruits (e.g., apples, 
peaches) and artificial sweeteners. A 2018 meta­analysis that evalu­
ated the efficacy of a diet low in FODMAPs in the treatment of IBS 
found that reducing FODMAP intake reduced global symptoms in the 
short term (relative risk [RR] 0.69, 95% confidence interval [CI] 0.54–
0.88); however, the studies were of variable quality.32 Use of the low­
FODMAP diet as first­line therapy in IBS is controversial, as many 
studies showing the efficacy of the diet are of limited generalizability, 
did not use an appropriate comparator, lacked blinding and were of 
a short duration.33 Moreover, there are few studies objectively evalu­
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Figure 2: A schematic summary of the factors that have been implicated in the pathophysiology of irritable bowel syndrome (IBS) within the context of 
the brain–gut axis. This figure also demonstrates the concept of visceral hypersensitivity in IBS, in which the pain threshold to rectosigmoid mechanical 
distension is lower in patients with IBS than in healthy controls, suggesting that the viscera are more sensitive.20
Box 2: Alarm, or red flag, features that would prompt 
the clinician to consider further investigations
• First presentation at age > 50 yr 
• Weight loss
• Rectal bleeding or masses
• Nocturnal symptoms
• History of recent antibiotic use
• Raised inflammatory markers
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subgroups of IBS. Given the complexities of this dietary intervention, 
we suggest that it should be instituted and monitored by a registered 
dietician with training and skills in this area.
Pharmacologic treatment
Pharmacologic therapies, which are directed at reducing symp­
toms such as constipation, diarrhea, bloating or pain, are sum­
marized in Table 1.
Constipation
A 2016 meta­analysis of both randomized and observational 
 studies of fibre supplementation in patients with IBS­C found that 
psyllium (ispaghula), a poorly fermented soluble fibre, is associated 
with an overall improvement in IBS and is moderately effective in 
managing constipation, although it is associated with gastrointes­
tinal adverse effects, such as bloating.34 Insoluble fibre, such as 
bran, has not been shown to have a beneficial effect in IBS.26 In 
Patient presenting with recurrent
abdominal pain and a change in 
bowel  habit for at least 3 months
Take a history and perform 
a clinical  examination
Rome IV criteria for IBS*
Recurrent abdominal pain, 
occurring on average at least 1 day 
per week in the previous 3 months, 
with at least 2 of the following:
•   Related to defecation
•   Associated with a change in 
frequency of stool
•   Associated with a change in 
appearance of stool




•   Try to delineate bowel habit by  
discontinuing any laxatives or 
loperamide — when established 
treat the most problematic  
•   Low FODMAP diet
•   SSRIs or TCAs if pain predominant 
•   Probiotics  
•   Psychological therapies
Exclude red flag symptoms
Consider targeted testing, e.g., CBC, IgA/
TTG, CRP, vitamin B12, folate, ferritin 
and fecal calprotectin
If present refer on 
appropriate pathway to 
exclude malignancy
If abnormalities seen, 
investigate further
and treat as appropriate
Educate and reassure — develop   
therapeutic partnership
Optimize treatment, e.g., lifestyle, 
exercise  and dietary triggers
Diarrhea-predominant IBS Constipation-predominant IBS
Diarrhea Pain or bloating
Options include
•   Loperamide
•   Eluxadoline
•   Rifaximin
Options include 
•   Antispasmodics
•   TCAs
•   Eluxadoline 
•   Rifaximin
•   Low FODMAP  
 diet
•   Probiotics
•   Psychological  
therapies
Constipation Pain or bloating
Options include
•   Psyllium
•   PEG-based
Second-line  
agents include
•   Linaclotide or  
plecanatide
•   Lubiprostone
Options include
•   Antispasmodics
•   SSRIs
•   Linaclotide
•   Probiotics
•   Low FODMAP diet





























Figure 3: A suggested algorithm for the management of irritable bowel syndrome (IBS). Care is ideally personalized based on predominant symptom, 
patient preference and local availability.27 *Criteria fulfilled with symptom onset at least 6 months before diagnosis. Note: CBC = complete blood count; 
CRP = C­reactive protein; FODMAP = fermentable oligo­, di­, mono­saccharides and polyols; IgA/TTG = immunoglobulin A tissue transglutaminase; 
PEG = polyethylene glycol; SSRI = selective serotonin reuptake inhibitor; TCA = tricyclic antidepressant.
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many patients, the addition of simple laxatives, such as prepara­
tions containing polyethylene glycol, may be effective in improving 
stool frequency and consistency.26 Lactulose can worsen distension 
and bloating, and therefore can exacerbate abdominal pain.35 Lina­
clotide and plecanatide are guanylate cyclase­C agonists and are 
second­line therapies in IBS­C when simple laxatives have provided 
insufficient relief of symptoms.36 In addition to their laxative effect, 
guanylate cyclase­C agonists have the benefit of improving abdom­
inal pain and bloating.37,38 Lubiprostone is a derivate of prostaglan­
din E1 that causes activation of the intestinal chloride channel type 
2 on the intraluminal aspect of enterocytes. This results in chloride, 
and subsequently water, efflux into the intestinal lumen, leading to 
more watery stools. Lubiprostone has been shown to have a bene­
ficial effect on stool consistency and abdominal pain in short­term 
use (1 month) but does not outperform placebo, except in abdom­
inal bloating, at 3 months.39
Table 1: Summary of the currently available pharmaceutical treatment options for irritable bowel syndrome26
Treatment, by 
symptom Mechanism of action Dosage Adverse effects















0.83 (0.73–0.94) 7 (4–25) $
Polyethylene 
glycol
Osmotic laxative 1–2 sachets per 









Linaclotide Guanylate cyclase­C 
agonist




0.81 (0.77–0.85) 6 (5–8) $$$
Plecanatide Guanylate cyclase­C 
agonist
3 mg once per 
day
Diarrhea 0.88 (0.84–0.92) 10 (8–14) $$$
Lubiprostone Type­2 chloride 
channel agonist




0.91 (0.87–0.95) 12.5 (8–25) $$$
Diarrhea
Loperamide µ­Opioid receptor 
agonist
2–4 mg up to 
3 times per day
Constipation, 
abdominal pain
0.44 (0.14 ­1.52) Unknown $
Eluxadoline† Mixed µ­opioid receptor 
and κ­opioid receptor 












relaxant — calcium 
channel blocker
50–100 mg once 
or twice per day
Stomach pain, fullness, 
nausea
0.65 (0.56–0.76) 5 (4–8) $
Peppermint oil Smooth muscle 
relaxant
1 capsule 











10 mg at night Sleepiness, 
constipation, dry mouth
0.65 (0.55–0.77) 4 (3.5–7) $$
SSRIs (e.g., 
citalopram)
Centrally acting visceral 
pain modulation




0.68 (0.51–0.91) 5 (3–16.5) $$
Modification of the microbiota
Rifaximin Poorly absorbed 
antibiotic
550 mg twice 




0.86 (0.81–0.91) 10.5 (8–16) $$$
Probiotics Regulation of intestinal 
microbial homeostasis, 





Gas and bloating 0.81 (0.74–0.88) 7 (5–12) $$
Note: CI = confidence interval, SSRI = selective serotonin reuptake inhibitor.
*Authors’ assessment of the cost of treatment from least expensive ($) to most expensive ($$$).
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Diarrhea
Loperamide is an opioid receptor agonist that does not cross 
the blood–brain barrier, and hence does not exert an analgesic 
effect. Using this opioid effect, there is a reduction in colonic 
motility, which allows an increased quantity of water to be 
reabsorbed from colonic contents. In turn, this results in hard, 
drier stools and diminished defecatory urgency. Although 
adverse events with loperamide are rare, some patients may 
develop constipation, which can be avoided using dose titra­
tion with liquid formulations. An alternative is eluxadoline, a µ­ 
and κ­opioid receptor agonist and δ­opioid receptor antag­
onist, which has been shown to improve stool consistency and 
reduce abdominal pain, although it is contraindicated in 
patients who have had a prior cholecystectomy.40,41 The 
5­hydroxytryptamine type 3 (5­HT3) receptor antagonists may 
also be effective in the management of IBS­D. Serotonin (5­HT) 
is a major mediator of afferent nerve signalling and exerts a 
prokinetic effect within the gut, with 5­HT3 receptor antagonists 
blocking vagal induction of 5­HT. Irritable bowel syndrome with 
diarrhea has been associated with several 5­HT abnormalities 
within the gut, including heightened numbers of 5­HT­containing 
enteroendocrine cells,42 increased postprandial 5­HT release43 
and reduced serotonin transporter messenger RNA in the 
colon.44,45 Previously, alosetron, a 5­HT3 receptor antagonist, 
was approved for use in IBS­D, although it is not available in 
Canada because of cases of ischemic colitis.46 Studies are ongo­
ing to evaluate ondansetron, which is typically used as an anti­
emetic in IBS­D.
Pain
Effectively managing abdominal pain in IBS can be challenging. 
Current pharmacologic options including antispasmodics, and 
low­dose tricyclic antidepressants (TCAs) and selective sero­
tonin reuptake inhibitors (SSRIs). The broad mechanism of 
action of antispasmodics is to induce muscular relaxation of 
the wall of the gastrointestinal tract. Hyoscine reduces acetyl­
choline binding at muscarinic receptors, which results in 
smooth muscle relaxation, although it can worsen constipation. 
Calcium channel blockers, such as pinaverium, also reduce 
smooth muscle contraction, and preparations containing pep­
permint oil can reduce symptoms.47 Mebeverine, a musculo­
tropic agent that reduces intestinal peristalsis, has been shown 
to reduce symptom burden in non–placebo­controlled stud­
ies.48 The mechanism of action of TCAs and SSRIs is incom­
pletely understood, but it is thought that they influence the 
afferent barrage of nociceptive signalling at the level of the spi­
nal dorsal horn and influence descending modulatory pain 
pathways.21,49 In addition, TCAs and SSRIs may positively affect 
comorbid anxiety and depression. Overall, meta­analytic evi­
dence suggests that antidepressants are efficacious in manag­
ing IBS.50 The most frequently used TCA is low­dose amitripty­
line (e.g., 10 mg at night), which can be titrated up. Tricyclic 
antidepressants have a number of anticholinergic adverse 
effects, which include constipation and are therefore most suit­
able for patients with IBS­D. In contrast, SSRIs can cause diar­
rhea and therefore may be considered in patients with IBS­C.
Interventions targeting the microbiota
Given the proposed role of the microbiota in the pathophysiol­
ogy of IBS, several studies have evaluated the role of interven­
tions that modify the microbiota. For instance, a large placebo­
controlled trial of rifaximin, a minimally absorbed antibiotic, has 
shown significant symptomatic improvement in patients with 
IBS who received treatment with rifaximin, although the number 
needed to treat was 10.6.51,52 A further study has evaluated the 
safety and efficacy of repeated treatment with rifaximin.53 Among 
patients who clinically responded to open­label treatment, 
about two­thirds experienced a relapse and were randomly 
assigned to receive repeat treatment with rifaximin or placebo. 
There was a small but statistically significant response in the 
group receiving treatment with rifaximin compared with the pla­
cebo group (38.1% v. 31.5%, p = 0.03), with the best response 
seen with respect to abdominal pain.53 A number of studies have 
provided evidence to support the role of probiotics in IBS, 
although variations in study design and specific probiotics used 
limit interpretability.54–56 Nevertheless, a proportion of patients 
derive benefit from probiotics and a pragmatic approach is to 
institute a month trial.
Psychological therapies
As a class of interventions, psychological treatments are effective 
in reducing overall symptom burden in IBS (RR 0.69, 95% CI 0.62–
0.76) according to a meta­analysis of RCTs, although the quality 
of the evidence is weak owing to study heterogeneity.50 Several 
techniques, including cognitive behavioural therapy (CBT), 
dynamic psychotherapy and hypnotherapy have been shown to 
be effective, as summarized in a recent review.57 Psychological 
therapies should be considered for patients who have not 
responded to first­ or second­line treatments after 3–6 months, 
or in whom there is a significant association between stress and 
symptoms, according to a recent international expert consen­
sus.27 In a 2008 RCT of self­administered CBT or psychotherapist­
delivered CBT compared with usual care in patients with moder­
ate to severe IBS, either form of CBT was found to improve 
quality of life and reduce IBS symptom severity in comparison 
with usual care.58 A case–control study found that gut­focused 
hypnotherapy, a technique that uses suggestion, imagery and 
relaxation directed toward the gastrointestinal tract, reduces 
gastrointestinal symptoms, putatively via changes in cognitive 
function leading to a reduction in visceral sensitivity.59 In a recent 
report of an audit of 1000 patients with IBS, hypnotherapy was 
associated with reduced abdominal pain, and improvements in 
symptoms and quality of life.60 Despite this evidence, the utility 
of psychological interventions in IBS is limited by availability of 
expert therapists.
Conclusion
Irritable bowel syndrome is a prevalent and multifactorial disor­
der whose pathophysiology remains incompletely understood. 
Diagnosis relies on the identification of chronic typical symptoms 
characterized by abdominal pain, bloating and change in fre­
quency or form of bowel habit. Although IBS is conventionally 
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subclassified according to predominant bowel habit, the syn­
drome likely encompasses a number of distinct pathophysiolo­
gies that result in similar clinical phenotypes. While several man­
agement options exist, further work is needed to individualize 
therapy, which may result in improved outcomes.
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